Advertisement


Matteo Lambertini, MD, on Preserving Fertility in Patients With Early Breast Cancer: Pooled Analysis

2017 San Antonio Breast Cancer Symposium

Advertisement

Matteo Lambertini, MD, of the Institut Jules Bordet, discusses the results of five clinical trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients (Abstract GS4-01).



Related Videos

Breast Cancer

Melinda Telli, MD, on Triple-Negative Breast Cancer: New Clinical Approaches

Melinda Telli, MD, of the Stanford University School of Medicine, discusses the current status of treatment for advanced TNBC, and new therapeutic strategies now being used for better outcomes.

Breast Cancer

Michael Gnant, MD, on Duration of Anastrozole Treatment: Results of the ABCSG-16 Trial

Michael Gnant, MD, of the Medical University of Vienna, discusses phase III study findings on giving an additional 2 vs an additional 5 years of anastrozole after the first 5 years of adjuvant endocrine therapy (Abstract GS3-01).

Breast Cancer

Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer (Abstract GS2-05).

Breast Cancer

Lisa A. Carey, MD, on Locally Recurrent or Metastatic Breast Cancer: Results of a CALGB/NCCTG Trial

Lisa A. Carey, MD, of the University of North Carolina, discusses the long-term follow-up of CALGB 40502/NCCTG N063H, a phase III study of weekly paclitaxel compared with weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (Abstract GS3-06).

Breast Cancer

Rowan T. Chlebowski, MD, PhD, on Weight Loss and Breast Cancer Risk: Results From the Women’s Health Initiative

Rowan T. Chlebowski, MD, PhD, of the City of Hope National Medical Center, discusses 11-year followup results that showed a significantly lower breast cancer incidence among women with a greater than 5% weight loss (Abstract GS5-07).

Advertisement

Advertisement




Advertisement